MedTrace Logo

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-18

No results posted yet for this study

Summary

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Conditions

  • Adenocarcinoma
  • Carcinoma, Pancreatic Ductal

Interventions

DRUG

Relacorilant

Relacorilant will be administered as capsules for oral dosing.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered via IV infusion.

DRUG

Gemcitabine

Gemcitabine will be administered via IV infusion.

Sponsors & Collaborators

Principal Investigators

  • Adrian Jubb · Corcept Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-27
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259317 on ClinicalTrials.gov